香港唯爾醫務中心
全方位的醫療服務中心
Price：$2,300
Alzheimer’s disease is the most common form of dementia. According to WHO data, Alzheimer’s disease accounts for 60-70% of dementia cases.
Symptoms of dementia may appear in some elderly individuals, but they are not a part of normal ageing. Notably, 5% of cases are early-onset Alzheimer’s disease. Understanding the genetic variants of Alzheimer’s disease helps in assessing the hereditary risk of both early- and late-onset forms.
According to medical literature, approximately 35-60% of patients with early-onset Alzheimer’s disease have a family history of the condition.
Carrying one copy of the APOE4 genetic variant increases the risk by 2 to 3 times compared to other patients; carrying two copies of the variant increases the risk of developing the disease by 10 to 15 times.
Test Description
The testing options are as follows:
- The CoGenesis® AD test covers 6 high-risk genes associated with early-onset Alzheimer’s disease. It is specifically designed for individuals already diagnosed with early-onset Alzheimer’s disease, those who suspect they may have early-onset AD, or individuals with family members affected by early-onset AD.
- The CoGenesis® APOE Genetic Test only covers the APOE gene, a high-risk gene associated with late-onset Alzheimer’s disease. It is specifically designed for individuals already diagnosed with late-onset AD, those who suspect they may have late-onset AD, or individuals with family members affected by late-onset AD.
What is the purpose of this genetic test?
- Understanding genetic variations in Alzheimer’s disease through our testing results can help assess the inherited risk of early-onset or late-onset Alzheimer’s disease.
- Knowing the possible disease-causing genes can assist doctors in formulating personalized treatments. Different genetic variations can affect the efficacy and safety of medications. For example, individuals with the APOE4 genetic variant may have a risk of brain swelling.
- Approximately 50% of early-onset Alzheimer’s disease patients have a family history of the disease. Therefore, individuals with family members affected by Alzheimer’s should consider whether they have a chance of carrying genetic variations associated with a high risk of Alzheimer’s disease.
Covered Genes
APP, PSEN1, PSEN2, APOE, TREM2, MAPT
Processing of Test Reports
The expected turnaround time for this test is 4 working weeks.
Sample collection method
You can make an appointment immediately by following the instructions below and come to the Hong Kong Well Clinic to have your saliva or blood sample collected.
